1 Modifiable risk factors and inflammation-related proteins in polymyalgia rheumatica: genome-

2 wide meta-analysis and Mendelian randomisation

- 3
- 4 Sizheng Steven Zhao<sup>1</sup>, Sarah L Mackie<sup>2,3</sup>, Susanna C Larsson<sup>4,5</sup>, Stephen Burgess<sup>6,7,8</sup>, Shuai Yuan<sup>4</sup>

5

- 6 1 Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science,
- 7 School of Biological Sciences, Faculty of Biological Medicine and Health, The University of
- 8 Manchester, Manchester Academic Health Science Centre, Manchester, UK
- 9 2 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK
- 3 National Institute for Health Research Leeds Biomedical Research Centre, Leeds Teaching Hospitals,
   University of Leeds, Leeds, UK
- 12 4 Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine,
- 13 Karolinska Institutet, Nobelsväg 13, 17177, Stockholm, Sweden
- 14 5 Department of Surgical Sciences, Uppsala University, Dag Hammarskjölds Väg 14B, 75185, Uppsala,
- 15 Sweden
- 16 6 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and
- 17 Primary Care, University of Cambridge, Cambridge, UK
- 18 7 Heart and Lung Research Institute, University of Cambridge, Cambridge UK
- 19 8 Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK

20

- 21 Correspondence to: Dr Sizheng S Zhao. Centre for Musculoskeletal Research, Division of
- 22 Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological
- 23 Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre,
- 24 Oxford Road, Manchester, M13 9LJ, UK. Email: <u>Sizheng.zhao@manchester.ac.uk</u>

## 26 Abstract

Objective: Polymyalgia rheumatica (PMR) is an age-related inflammatory disease of unknown cause.
 We aimed to identify potentially modifiable risk factors and therapeutic targets for preventing or
 treating PMR.

30 Methods: We meta-analysed genetic association data from 8,156 cases of PMR (defined using

diagnostic codes and self-report) and 416,495 controls of European ancestry from the UK Biobank

32 and FinnGen. We then performed Mendelian randomization analyses to estimate the association

between eight modifiable risk factors (using data from up to 1.2 million individuals) and 65

34 inflammation-related circulating proteins (up to 55,792 individuals), using the inverse variance

35 weighted and pleiotropy robust methods.

36 **Results:** We identified three novel genome-wide significant loci in the *IL1R1*, *NEK6* and *CCDC88B* 

37 genes and confirmation of previously described associations with *HLA-DRB1* and *ANKRD55*.

38 Genetically predicted smoking intensity (OR 1.32; 95%Cl 1.08-1.60; p=0.006) and visceral adiposity

39 (OR 1.22; 95%Cl 1.10-1.37; p=3.10x10<sup>-4</sup>) were associated with PMR susceptibility. Multiple circulating

40 proteins related to IL-1 family signaling were associated with PMR. IL-1 receptor-like 2, also known as

41 IL-36 receptor (OR 1.25; p=1.89x10<sup>-32</sup>), serum amyloid A2 (OR 1.06, 9.91x10<sup>-10</sup>) and CXCL6 (OR 1.09,

42 p=4.85x10<sup>-7</sup>) retained significance after correction for multiple testing.

43 **Conclusion:** Reducing smoking and visceral adiposity at a population level might reduce incidence of

44 PMR. We identified proteins that may play causal roles in PMR, potentially suggesting new

therapeutic opportunities. Further research is needed before these findings are applied to clinical
practice.

47 Keywords: genome-wide meta-analysis, interleukin-1, smoking, obesity, adiposity, polymyalgia
48 rheumatica

49 Key messages:

50 1) Three novel PMR risk loci were identified in *IL1R1, NEK6* and *CCDC88B*.

2) Several circulating proteins, notably those involved in IL-1 family signalling, are associated with
PMR susceptibility.

53 3) Visceral adiposity and cigarette smoking are causally associated with risk of PMR.

54

55

#### 56 Introduction

- 57 Polymyalgia rheumatica (PMR) is an age-related inflammatory disease of unknown cause (1). The
- 58 pattern of inflammation of PMR centres on certain tendon, ligaments, and joint capsules, but
- 59 without radiographic change in adjacent articular bone (2). There is overlap with giant cell arteritis
- 60 (GCA) and both diseases have been postulated to preferentially initiated at mechanically-stressed
- sites (3,4). The intense systemic inflammatory response of PMR hampers efforts to disentangle true
- 62 causal factors from epiphenomena related to systemic inflammation or compensatory/counter-
- 63 regulatory mechanisms. To date, poor understanding of PMR aetiopathogenesis has been a barrier to
- 64 progress in its definition, diagnosis, and treatment. Currently, long-term oral glucocorticoids are the
- 65 primary treatment used, at the cost of substantial treatment toxicity (1).
- 66 Like GCA, PMR is more commonly diagnosed in northern European countries, but genetic and
- 67 environmental contribution to this geographical distribution is unclear. Genome-wide association
- 58 studies have yielded mechanistic insights into GCA implicating angiogenesis and neutrophils (5).
- 69 Historically, genetic association data in PMR has been contradictory or inconclusive due to
- vunderpowering and historic use of candidate gene methods (1). Recently, we reported that
- 71 genetically proxied IL-6 receptor (6) and IL-1 receptor antagonism (7) are both associated with
- reduced risk of PMR. In the current genetic investigation, we aimed to identify potentially modifiable
- risk factors and inflammation-related circulating proteins as targets of intervention for preventing or
- 74 treating PMR.

# 75 Methods

# 76 <u>Study design</u>

- 77 We performed a genome wide association study (GWAS) meta-analysis using data from the UK
- 78 Biobank and FinnGen. Genetic association data was used in Mendelian randomization (MR) analyses
- of selected modifiable risk factors and inflammation-related circulating proteins. Ethical approval was
- 80 obtained by the FinnGen and UK Biobank (application 72723) studies to which participants provided
- 81 written informed consent.

## 82 <u>GWAS of UK Biobank and FinnGen</u>

- 83 The UK Biobank is a cohort study of approximately 500,000 individuals aged 40-69 years, recruited
- 84 between 2006 and 2010 (8). It includes self-reported data on diseases, linked hospital admissions
- data, the national death register, and primary care data for a subset of ~225,000 participants. Quality
- 86 control of UK Biobank genotype data has been described previously (8). The current analysis was
- 87 restricted to unrelated (kinship≥0.084) individuals of self-reported White-British ancestry, with

88 concordant submitted and genetically inferred sex. GWAS was performed using SNPTEST v2.5.4,

- adjusting for the first four principal components derived using cases and controls. Variants with
- 90 minor allele frequency of <0.01 and INFO score of <0.5 were excluded. PMR was defined using any of
- 91 the following: ICD 10 code M353 (from fields 41270, 40001 or 40002), self-report (code 1377 in field
- 92 20002), or Read code N20.. or XE1FJ in linked primary care data. GWAS comprised 4,285 cases of
- 93 PMR (3180 ICD, 1073 self-report, 1239 Read) and 17,140 randomly selected controls without PMR
- 94 (1:4 ratio to reduce case-control imbalance that can increase type I error (9,10)) and was adjusted for
- 95 the first four principal components.
- 96 FinnGen is a large research study comprising genetic and health data from 500,000 Finnish
- 97 participants. Quality control steps have been previously described. We used Release 10 (December
- 98 2023) summary-level data on PMR, comprising 3,871 cases and 399,355 controls. PMR was defined
- 99 by ICD code 10th (M353), 9th (725), or 8th (4463) revisions. Genetic associations were adjusted for
- age, sex, principal components, and genotyping batch.
- 101 We combined summary statistics from UK Biobank and FinnGen under a fixed effects model using
- 102 the METAL software (11) and examined the heterogeneity in SNP-PMR associations across the two
- studies. LD Score regression was used to evaluate the heritability, genomic inflation factor (lambda),
- 104 and intercept (12).

# 105 <u>Mendelian randomization analysis</u>

- 106 MR analyses used genetic association data from the above GWAS meta-analysis comprising a total of
- 107 8,156 PMR cases and 416,495 controls. We first investigated the association between eight
- 108 modifiable environmental or lifestyle risk factors and PMR, including three obesity indicators (body
- 109 mass index (BMI) (13), waist circumference (14), and visceral adiposity (15)) and five lifestyle factors
- 110 (smoking initiation (16), smoking intensity measured in cigarettes per day (16), alcohol (16) and
- 111 coffee consumption (17), and moderate-to-vigorous physical activity (18)). To identify potential
- 112 therapeutic targets, we conducted MR analyses of 66 inflammation-related circulating proteins (19–
- 113 21) in relation to PMR susceptibility. **Table S1** provides information on GWASs from which genetic
- association data for these exposures were derived.
- 115 For the eight modifiable risk factors, we selected SNPs associated with the exposures of interest at
- 116 the genome-wide significance threshold (P<sup> $\square$ </sup> < $\mathbb{D}$ 5×10<sup>-8</sup>) from their respective GWASs. For the
- 117 inflammation-related circulating proteins, only *cis*-acting SNPs (i.e., within ±250 kb of the gene
- encoding the relevant protein) were selected. For all exposures, we excluded SNPs exhibiting high
- linkage disequilibrium (LD) ( $r^2 > 0.01$ , using the 1000 Genomes European reference panel), retaining

- 120 only the SNP with the lowest *P* value from the GWAS association. For inflammation-related
- 121 circulating proteins with a limited number of SNPs as genetic instruments, we sought proxy SNPs that

had a high LD  $(r^2 > 0.8)$  with those SNPs that were not available.

- 123 For exposures with two SNPs as instruments, we used the inverse variance weighted method under a
- 124 fixed effects model to estimate their association with risk of PMR; otherwise, we used the
- 125 multiplicative random effects inverse variance weighted method. For exposures proxied by multiple
- 126 SNPs, we conducted sensitivity analyses, including the weighted median and MR-Egger methods, to
- 127 validate the robustness of our findings and detect and address potential horizontal pleiotropy. We
- 128 used Cochran's Q value to assess the heterogeneity among the SNP estimates. Multiple testing
- 129 corrections were implemented using the Benjamini-Hochberg false discovery rate (FDR) method. All
- analyses were based on two-sided tests and performed using the TwoSampleMR and
- 131 MendelianRandomization packages in R (version 4.1.1).

#### 132 Results

## 133 <u>Genome-wide association analysis</u>

- 134 This GWAS meta-analysis included 424,651 individuals (8,156 cases and 416,495 non-cases).
- Assuming a lifetime prevalence of 2% among those of European ancestry (22), the heritability of PMR
- 136 on a liability scale explained by common genetic variants (minor allele frequency (MAF) ≥0.05) was
- estimated at  $h^2 \mathbb{I} = 0.09$  (95% CI 0.06-0.11). The genomic inflation factor,  $\lambda_{GC}$ , was calculated to be
- 138 1.06, suggesting a minimal inflation due to population stratification or other confounding factors.
- 139 The LD score regression intercept was estimated at 0.99 (standard error=0.008), indicating a good
- alignment with the null expectation of no polygenicity.
- 141 We annotated five genome-wide significant loci (Figure 1), with *IL1R1* (rs11694915), *NEK6*
- 142 (rs748741), CCDC88B (rs615540) being previously unreported (Table 1), and HLA-DRB1 and ANKRD55
- 143 consistent with prior reports (23). rs2760985 (tagging *HLA-DRB1*) was the most pronounced
- association observed. It was also the only SNP with statistical evidence of heterogeneity across
- 145 FinnGen and UK Biobank cohorts, but estimates were directionally concordant (**Table S2**).

#### 146 Mendelian randomization analysis

- 147 Of the eight modifiable risk factors, genetically predicted levels of BMI, visceral adiposity and
- smoking intensity (cigarettes per day) were associated with PMR (Figure 2). Genetically predicted
- smoking intensity was associated with 1.32-fold higher odds of PMR per standard deviation (SD)
- increase (95%Cl 1.08-1.60; p=0.006). Higher genetically predicted BMI (OR 1.16 per SD increase;
- 151 95%Cl 1.03-1.31; p=0.013) and visceral adiposity (OR 1.22 per SD increase; 95%Cl 1.10-1.37;

- p=3.10×10<sup>-4</sup>) were also associated with PMR risk. After false discovery rate (FDR) multiple-testing
   correction, associations with visceral adiposity and smoking intensity retained significance. There
   was no statistical evidence of directional pleiotropy (Table S3). Genetically predicted levels of the
   other modifiable risk factors showed no significant associations with PMR susceptibility.
- 156 Of the inflammation-related circulating proteins, suitable genetic instruments were identified for 65. 157 Genetically predicted levels of 12 inflammatory markers were associated with susceptibility to PMR 158 (Figure 3) including various proteins in the IL-1 family signaling pathways. After adjusting for multiple 159 testing, only the associations for IL-1 receptor-like 2 (also known as IL-36 receptor) (OR 1.25; 95%CI 1.21. 1.30: p=1.89x10<sup>-32</sup>), serum amyloid A2 protein (OR 1.06; 95%CI 1.04, 1.07; p=9.91x10<sup>-10</sup>) and 160 CXCL6 (CXC motif chemokine 6) (OR 1.09; 95%Cl 1.05, 1.13; p=4.85x10<sup>-7</sup>) remained significant. Full 161 162 results for all inflammation-related circulating proteins are shown in Table S4. The three SNPs used 163 to instrument IL-1 receptor-like 2 are in close proximity to the *IL1R1* SNP identified in GWAS and may 164 represent the same underlying association; rs3917265 is correlated with rs11694915 (*IL1R1*) with r<sup>2</sup>
- 165 of 0.11).

## 166 Discussion

This, the largest GWAS meta-analysis of PMR to date, has identified three novel loci in the *IL1R1*, *NEK6* and *CCDC88B* genes and confirmation of previously described associations with *HLA-DRB1* and *ANKRD55*. Moreover, we found causal associations between PMR and levels of circulating proteins
involved in IL-1 family signalling (potentially explained by the same IL-1 GWAS signal), the acute
phase response (serum amyloid A2), and neutrophil chemotaxis, angiogenesis and tendon repair
(CXCL6). MR analyses identified visceral adiposity and cigarette smoking as modifiable risk factors for
PMR.

174 The next largest published genetic association study of PMR, to our knowledge, was an exome-wide 175 analysis of 559 cases and 15,620 controls (24). That prior study identified two SNPs in the HLA 176 region, rs3096702 (which the authors could not replicate) upstream of Notch4 and rs6910071 in 177 C6orf10. A conference abstract that similarly combined UK Biobank and an earlier release of FinnGen 178 data identified SNPs close to the HLA-DRB1 gene and the same intronic variant in ANKRD55 as in the 179 current study (23). ANKRD55 variants have been linked to expression of the neighbouring IL6ST gene 180 in various immune cells (25). IL6ST encodes part of a cytokine receptor complex that act as a signal 181 transducer shared by multiple cytokines, including IL-6. These findings are supported by a prior 182 Mendelian randomization study linking genetically proxied IL-6R inhibition and reduced PMR risk (6), 183 and additionally by the current results for IL-6 receptor subunit alpha. These genetic findings may be

viewed as supporting the relevance of IL-6 signalling in PMR, consistent with clinical trial efficacy of
IL-6R inhibition (26,27).

186 Genes encoding proteins involved in IL-1 signalling have been identified in prior candidate gene 187 studies of PMR, for example IL1RN (28). We previously showed that genetically proxied IL-1R 188 antagonism is associated with PMR risk (7). Multiple IL-1 family members were implicated in the 189 current hypothesis-free genome-wide and inflammatory-protein-wide association analyses, but most 190 did not survive correction for multiple testing. Canakinumab, an IL-1b inhibitor, reduced PMR disease 191 activity in a 2-week proof of concept study of five patients (29) but large-scale trials of IL-1 192 antagonism in PMR are lacking. The only IL-1 family protein to survive multiple testing was IL-1 193 receptor like 2, also known as the IL-36 receptor. Activation of the IL-36 receptor can induce trained 194 immunity in monocytes (30) and has a variety of other functions (31) depending on cellular context. 195 IL-36 receptor inhibitors have been approved for generalised pustular psoriasis (32) but not yet 196 trialled in PMR.

197 Serum amyloid A2, one of the inducible serum amyloid A (SAA) proteins, was the only hepatic acute-198 phase protein that survived multiple testing in our analysis. In addition to being highly inducible in 199 liver by IL-6 and IL-1, this lipophilic protein also acts as a damage-associated molecular pattern 200 (DAMP) molecule and may be secreted by macrophages or adipocytes (33,34). In vitro, SAA can 201 induce macrophage IL-1b secretion via activation of the NLRP3 inflammasome; in the circulation this 202 effect is abrogated by SAA binding to high-density lipoprotein, which inactivates it (35). SAA can also 203 recruit neutrophils and activate their glycolytic pathways in vitro (36). In an ex vivo model of GCA 204 serum amyloid A can promote angiogenesis (37). Serum amyloid A1 and A2 have also been 205 implicated in other Th17-associated inflammatory diseases (38). A phase III trial of secukinumab for 206 PMR is ongoing (NCT04930094).

207 CXCL6, also known as GCP-2, is one of the pro-angiogenic chemokines, originally described as a 208 neutrophil chemoattractant. In macrophage and endothelial cell lines, SAA synergises with CRP to 209 upregulate CXCL6 alongside CXCL8, another neutrophil chemoattractant (39). Fibroblasts from 210 patients with ulcerative colitis produce IL-6 upon stimulation by IL-17 (40). In a study that used 211 single-cell techniques to characterise cell subpopulations from healthy and diseased human tendons 212 taken from near the myotendinous junction, CXCL6 was among the inflammatory/alarmin genes that 213 were overexpressed by microfibril-associated tenocytes in chronic tendinopathy (41). Intriguingly, in 214 a model of tendon injury in the horse, IL-1b, released after injury, "licensed" mesenchymal stem cells 215 (MSCs) to secrete an array of reparative and immunomodulatory factors, including CXCL6 (42). In the 216 mouse meniscus-defect model, extracellular vesicles (EVs) secreted by human MSCs upregulated

217 local chondrocyte and MSC CXCL5 and CXCL6 expression; the EVs promoted chondrocyte growth and

218 migration and this effect could be abrogated by blocking CXCL5 and CXCL6, or their common

receptor. It was concluded that CXCL5 and CXCL6 were involved in stimulating cartilage response to

220 injury (43). CXCL6 is a multifunctional molecule. Via its action on (human) CXCR1/2, it promotes

221 cartilage repair (44); but also, via binding to local glycosaminoglycans, CXCL6 creates a chemokine

concentration gradient that brings in neutrophils that can exacerbate tissue damage (45).

223 Challenges of interpreting observational studies illustrate the complex relationship between

adiposity, PMR susceptibility and glucocorticoid toxicity. On the one hand, active (undiagnosed) PMR

225 causes weight loss. IL-6 has a key role in thermoregulation; it is produced by muscle in response to

exercise, promoting lipolysis, and is also secreted by beige adipocytes in response to cold exposure.

227 IL-6 itself promotes further "beiging" to convert pro-inflammatory white adipose tissue towards

thermogenic "beige" adipose tissue (46), promoting energy utilisation and weight loss. On the other

229 hand, glucocorticoid treatment causes visceral adiposity, which is strongly correlated with

230 cardiovascular risk. Aging can also lead to accumulation of visceral adipose tissue. Similarly, smoking

can alter both innate and adaptive immune responses, with persistent effects especially on adaptive

immunity long after individuals quit smoking (47) as well as impairing tissue perfusion, healing and

angiogenesis. It remains to be seen whether smoking and adiposity, as well as being amenable to

lifestyle change, might also prove useful for identifying patients with PMR who are at higher risk ofadverse outcomes.

This study highlights previously-unappreciated aspects of the aetiopathogenesis of PMR, a disease with a characteristic pattern of inflammation of certain tendon and ligament sites (2) that are under high mechanical stress (4). In young individuals, mechanical stress from physical activity or high BMI elicits in adaptive changes such as increase in cross-sectional area and tendon stiffness; however, this ability to respond to mechanical stress is lost in older people (48). Visceral adipose tissue contains activated immune cells producing IL-1b and IL-6 with systemic effects. Fat deposition in and around muscles, entheses and tendons occurs with aging or obesity, and may contribute to chronic

tendinopathy (49).

Antagonistic pleiotropy is a theory to explain why genes causing age-associated diseases can persist in populations despite natural selection. Hypothetically, a genetic tendency to greater IL-1 induced local CXCL6 release might hasten healing of injuries in youth, and protect joints from damage; but delayed healing in aging, or the pro-inflammatory effect of visceral adiposity, would lead to a chronic damage-repair cycle with persistent local inflammation and neoangiogenesis, that might be

exacerbated by the same genetic tendency. This hypothesis could be further investigated in healthy
volunteers of different genotypes, ages and visceral adiposity levels.

251 The comparatively large number of PMR cases is a strength of the current study, but there are also 252 limitations. First, our analyses focused on populations of European ancestry, potentially limiting the 253 generalizability of our findings to other populations. Second, PMR cases were defined using clinical 254 diagnostic codes, which may introduce misclassification. There is a lack of genetic data from large-255 scale inception cohorts of well-characterised PMR patients. Furthermore, there are no formal 256 diagnostic criteria for PMR and thus no gold standard other than expert clinical opinion. In practice, 257 the clinical diagnostic boundaries between PMR and "elderly-onset" seronegative RA are defined by 258 clinical convention and consensus. Better mechanistic understanding of the differences between 259 these two diseases, and between PMR and GCA, may enable dividing-lines between these diseases 260 to be drawn more accurately in future. Multimodal approaches including genetic evidence will be

261 needed.

262 In conclusion, this study identified three novel PMR risk loci in *IL1R1*, *NEK6* and *CCDC88B* and

263 confirmed previously described associations with *HLA-DRB1* and *ANKRD55*. The importance of the

264 IL1R1 locus was supported by causal associations between circulating proteins involved in IL-1 family

signalling and PMR risk. Results also suggested visceral adiposity and cigarette smoking to be

- 266 potentially modifiable risk factors for PMR. These findings improve the current understanding of the
- 267 genetic underpinning of PMR, and propose potential new avenues for prevention and treatment.

268

269

## 270 Acknowledgements

271 SSZ is supported by a National Institute for Health Research (NIHR) Academic Clinical Lectureship. 272 SLM is supported in part by the NIHR Leeds Biomedical Research Centre (grant NIHR203331). The 273 views expressed are those of the authors and not necessarily those of the National Health Service, 274 the NIHR, or the Department of Health. This work was supported by Versus Arthritis (grant number 275 21173, grant number 21754 and grant number 21755) and by the NIHR Manchester Biomedical 276 Research Centre. SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United Kingdom 277 Research and Innovation Medical Research Council (MC UU 00002/7, MC UU 00040/01). 278 Data availability statement: UK Biobank data are available to all bona fide researchers for use in 279 health-related research that is in the public interest. The application procedure is described at 280 www.ukbiobank.ac.uk. GWAS meta-analysis data will be made publicly available upon publication.

- 281 Ethics approval: Ethical approval was obtained by the UK Biobank study. The current analysis was
- 282 performed under application number 72723.
- 283 Patient and Public Involvement: Patients or the public were not involved in the design, or conduct,
- or reporting, or dissemination plans of this research.
- 285 Conflicts of Interest: SLM reports: Consultancy on behalf of her institution for Roche/Chugai, Sanofi,
- 286 AbbVie, AstraZeneca, Pfizer; Investigator on clinical trials for Sanofi, GSK, Sparrow;
- 287 speaking/lecturing on behalf of her institution for Roche/Chugai, Vifor, Pfizer, UCB, Novartis,
- 288 Fresenius Kabi and AbbVie; chief investigator on STERLING-PMR trial, funded by NIHR; patron of the
- 289 charity PMRGCAuk. No personal remuneration was received for any of the above activities. Support
- from Roche/Chugai to attend EULAR2019 in person and from Pfizer to attend ACR Convergence 2021
- virtually. All other authors declare no conflicts of interest that could bias this work.

# 292 References

- Espígol-Frigolé G, Dejaco C, Mackie SL, Salvarani C, Matteson EL, Cid MC. Polymyalgia
   rheumatica. The Lancet. 2023 Oct 21;402(10411):1459–72.
- Owen CE, Poon AMT, Liu B, Liew DFL, Yap LP, Yang V, et al. Characterising polymyalgia rheumatica
   on whole-body 18F-FDG PET/CT: an atlas. Rheumatol Adv Pract. 2024 Feb 20;8(1):rkae003.
- Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017 Oct;13(10):578–92.
- Mackie SL, Owen CE, Buchanan RRC, McGonagle D. A shared basis for overlapping
   immunopathologies in giant cell arteritis and polymyalgia rheumatica. The Lancet Rheumatology.
   2021 Dec 1;3(12):e826-9.
- Borrego-Yaniz, G, Ortiz-Fernández, L, Madrid-Paredes, A et al. (49 more authors) (Accepted:
   2024) Angiogenesis- and NETosis-related risk loci involved in giant cell arteritis susceptibility by a
   genome-wide association study. The Lancet Rheumatology. ISSN 2665-9913 (In Press).
- 306 6. Zhao SS, Gill D. Genetically proxied IL-6 receptor inhibition and risk of polymyalgia rheumatica.
  307 Ann Rheum Dis. 2022 Jun 14;annrheumdis-2022-222578.
- Zhao SS, Rajeswaran T, Mackie SL, Yarmolinsky J. Genetically proxied IL-1 receptor antagonism
   and risk of polymyalgia rheumatica. Rheumatology. 2024 Feb 1;63(2):e43-4.
- 8. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9.
- Zengini E, Hatzikotoulas K, Tachmazidou I, Steinberg J, Hartwig FP, Southam L, et al. Genome wide analyses using UK Biobank data provide insights into the genetic architecture of
   osteoarthritis. Nat Genet. 2018 Apr;50(4):549–58.
- Zhou W, Nielsen JB, Fritsche LG, Dey R, Gabrielsen ME, Wolford BN, et al. Efficiently controlling
   for case-control imbalance and sample relatedness in large-scale genetic association studies. Nat
   Genet. 2018 Sep;50(9):1335–41.
- Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association
   scans. Bioinformatics. 2010 Sep 1;26(17):2190–1.
- Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Schizophrenia Working Group of the
   Psychiatric Genomics Consortium, et al. LD Score regression distinguishes confounding from
   polygenicity in genome-wide association studies. Nat Genet. 2015 Mar;47(3):291–5.
- Pulit SL, Stoneman C, Morris AP, Wood AR, Glastonbury CA, Tyrrell J, et al. Meta-analysis of
   genome-wide association studies for body fat distribution in 694 649 individuals of European
   ancestry. Human Molecular Genetics. 2019 Jan 1;28(1):166–74.
- Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New genetic loci
   link adipose and insulin biology to body fat distribution. Nature. 2015 Feb 12;518(7538):187–96.

- Karlsson T, Rask-Andersen M, Pan G, Höglund J, Wadelius C, Ek WE, et al. Contribution of
   genetics to visceral adiposity and its relation to cardiovascular and metabolic disease. Nat Med.
   2019 Sep;25(9):1390–5.
- Saunders GRB, Wang X, Chen F, Jang SK, Liu M, Wang C, et al. Genetic diversity fuels gene
   discovery for tobacco and alcohol use. Nature. 2022 Dec;612(7941):720–4.
- 333 17. Zhong VW, Kuang A, Danning RD, Kraft P, van Dam RM, Chasman DI, et al. A genome-wide
  334 association study of bitter and sweet beverage consumption. Hum Mol Genet. 2019 Jul
  335 15;28(14):2449–57.
- Wang Z, Emmerich A, Pillon NJ, Moore T, Hemerich D, Cornelis MC, et al. Genome-wide
  association analyses of physical activity and sedentary behavior provide insights into underlying
  mechanisms and roles in disease prevention. Nat Genet. 2022 Sep;54(9):1332–44.
- 19. Yarmolinsky J, Robinson JW, Mariosa D, Karhunen V, Huang J, Dimou N, et al. Association
  between circulating inflammatory markers and adult cancer risk: a Mendelian randomization
  analysis. eBioMedicine [Internet]. 2024 Feb 1 [cited 2024 Mar 1];100. Available from:
  https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00026-4/fulltext
- Pietzner M, Wheeler E, Carrasco-Zanini J, Raffler J, Kerrison ND, Oerton E, et al. Genetic
  architecture of host proteins involved in SARS-CoV-2 infection. Nat Commun. 2020 Dec
  16;11(1):6397.
- Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the
   human plasma proteome. Nature. 2018 Jun;558(7708):73–9.
- 22. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, et al. The Lifetime
  Risk of Adult-Onset Rheumatoid Arthritis and Other Inflammatory Autoimmune Rheumatic
  Diseases. Arthritis Rheum. 2011 Mar;63(3):633–9.
- 351 23. Hocaoglu M, Mikdashi J, Perry J, Hong C. Association of HLA-DRB1 and ANKRD55/IL6ST Regions
   352 with Polymyalgia Rheumatica Diagnosis: A Genome Wide Association Study from UK Biobank
   353 and FinnGen [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9).
- 354 https://acrabstracts.org/abstract/association-of-hla-drb1-and-ankrd55-il6st-regions-with-
- polymyalgia-rheumatica-diagnosis-a-genome-wide-association-study-from-uk-biobank-and finngen/. Accessed April 14, 2024.
- 357 24. Mosley JD, Witte JS, Larkin EK, Bastarache L, Shaffer CM, Karnes JH, et al. Identifying genetically
   358 driven clinical phenotypes using linear mixed models. Nat Commun. 2016 Apr 25;7:11433.
- 359 25. Mena J, Alloza I, Tulloch Navarro R, Aldekoa A, Díez García J, Villanueva Etxebarria A, et al.
  360 Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55-IL6ST Gene
  361 Region in Immature Dendritic Cells. Front Immunol. 2021;12:816930.
- 362 26. Bonelli M, Radner H, Kerschbaumer A, Mrak D, Durechova M, Stieger J, et al. Tocilizumab in
  363 patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised
  364 controlled trial. Annals of the Rheumatic Diseases [Internet]. 2022 Feb 24 [cited 2022 Mar 29];
  365 Available from: https://ard.bmj.com/content/early/2022/02/23/annrheumdis-2021-221126
- Spiera RF, Unizony S, Warrington KJ, Sloane J, Giannelou A, Nivens MC, et al. Sarilumab for
   Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper. New England Journal of
   Medicine. 2023 Oct 5;389(14):1263–72.

- 369 28. Alvarez-Rodriguez L, Carrasco-Marin E, Lopez-Hoyos M, Mata C, Fernandez-Prieto L, Ruiz-Soto M,
  370 et al. Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory
  371 chronic conditions: Association of IL-1RN\*2/2 genotype with polymyalgia rheumatica. Hum
  372 Immunol. 2009 Jan;70(1):49–54.
- 29. A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of
  Secukinumab (anti-IL17 mAb), Canakinumab (anti-IL-1 b mAb), or Corticosteroids on Initial
  Disease Activity Scores in Patients with PMR, Followed By an Open-Label Extension to Assess
  Safety and Effect Duration [Internet]. ACR Meeting Abstracts. [cited 2024 Mar 1]. Available from:
  https://acrabstracts.org/abstract/a-2-week-single-blind-randomized-3-arm-proof-of-concept-
- 378 study-of-the-effects-of-secukinumab-anti-il17-mab-canakinumab-anti-il-1-b-mab-or-
- 379 corticosteroids-on-initial-disease-activity-scores-in-p/
- 30. Teufel LU, Netea MG, van de Veerdonk FL, Dinarello CA, Joosten LAB, Arts RJW. Opposing Effects
   of Interleukin-36γ and Interleukin-38 on Trained Immunity. Int J Mol Sci. 2023 Jan 24;24(3):2311.
- 382 31. Han Y, Huard A, Mora J, da Silva P, Brüne B, Weigert A. IL-36 family cytokines in protective versus
   383 destructive inflammation. Cell Signal. 2020 Nov;75:109773.
- 384 32. Morita A, Strober B, Burden AD, Choon SE, Anadkat MJ, Marrakchi S, et al. Efficacy and safety of
   subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2):
   an international, multicentre, randomised, placebo-controlled trial. The Lancet. 2023 Oct
   28;402(10412):1541-51.
- 388 33. Sack GH. Serum amyloid A a review. Mol Med. 2018 Aug 30;24:46.
- 34. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase reactant. Eur J
   Biochem. 1999 Oct;265(2):501–23.
- 391 35. Shridas P, De Beer MC, Webb NR. High-density lipoprotein inhibits serum amyloid A-mediated
   392 reactive oxygen species generation and NLRP3 inflammasome activation. J Biol Chem. 2018 Aug
   393 24;293(34):13257–69.
- 36. He M, Liu Y, Chen S, Deng H, Feng C, Qiao S, et al. Serum amyloid A promotes glycolysis of
  neutrophils during PD-1 blockade resistance in hepatocellular carcinoma. Nat Commun. 2024
  Feb 26;15:1754.
- 37. O'Neill L, Rooney P, Molloy D, Connolly M, McCormick J, McCarthy G, et al. Regulation of
  Inflammation and Angiogenesis in Giant Cell Arteritis by Acute-Phase Serum Amyloid A. Arthritis
  Rheumatol. 2015 Sep;67(9):2447–56.
- 400 38. Lee JY, Hall JA, Kroehling L, Wu L, Najar T, Nguyen HH, et al. Serum Amyloid A Proteins Induce
   401 Pathogenic TH17 Cells and Promote Inflammatory Disease. Cell. 2020 Jan 9;180(1):79-91.e16.
- 402 39. Liu D, Chen Y, Wang Y, Lei M, Chen L, Liang R, et al. Combination of Serum Amyloid A and C403 Reactive Protein Exhibit Synergistic Effect in Angiogenesis by Inducing Inflammation and Vascular
  404 Network. Front Oncol. 2020 Dec 8;10:576207.
- 40. Kerami Z, Duijvis NW, Vogels EW, van Dooren FH, Moerland PD, Te Velde AA. Effect of interleukin17 on gene expression profile of fibroblasts from Crohn's disease patients. J Crohns Colitis. 2014
  407 Oct;8(10):1208–16.


- 408 41. Kendal AR, Layton T, Al-Mossawi H, Appleton L, Dakin S, Brown R, et al. Multi-omic single cell
  409 analysis resolves novel stromal cell populations in healthy and diseased human tendon. Sci Rep.
  410 2020 Sep 3;10(1):13939.
- 41. Koch DW, Berglund AK, Messenger KM, Gilbertie JM, Ellis IM, Schnabel LV. Interleukin-1β in
  412 tendon injury enhances reparative gene and protein expression in mesenchymal stem cells.
  413 Front Vet Sci. 2022 Aug 11;9:963759.
- 43. Kawata K, Koga H, Tsuji K, Miyatake K, Nakagawa Y, Yokota T, et al. Extracellular vesicles derived
  from mesenchymal stromal cells mediate endogenous cell growth and migration via the CXCL5
  and CXCL6/CXCR2 axes and repair menisci. Stem Cell Research & Therapy. 2021 Jul 22;12(1):414.
- 44. Sherwood J, Bertrand J, Nalesso G, Poulet B, Pitsillides A, Brandolini L, et al. A homeostatic
  function of CXCR2 signalling in articular cartilage. Ann Rheum Dis. 2015 Dec;74(12):2207–15.
- 45. Caxaria S, Kouvatsos N, Eldridge SE, Alvarez-Fallas M, Thorup A, Cici D, et al. Disease modification
  and symptom relief in osteoarthritis using a mutated GCP-2/CXCL6 chemokine. EMBO Mol Med.
  2022 Dec 12;15(1):e16218.
- 46. Ghesmati Z, Rashid M, Fayezi S, Gieseler F, Alizadeh E, Darabi M. An update on the secretory
  functions of brown, white, and beige adipose tissue: Towards therapeutic applications. Rev
  Endocr Metab Disord. 2024 Apr 1;25(2):279–308.
- 425 47. Saint-André V, Charbit B, Biton A, Rouilly V, Possémé C, Bertrand A, et al. Smoking changes
  426 adaptive immunity with persistent effects. Nature. 2024 Feb;626(8000):827–35.
- 427 48. Tomlinson DJ, Erskine RM, Morse CI, Pappachan JM, Sanderson-Gillard E, Onambélé-Pearson GL.
  428 The combined effects of obesity and ageing on skeletal muscle function and tendon properties in
  429 vivo in men. Endocrine. 2021;72(2):411–22.
- 430 49. Lui PPY, Yung PSH. Inflammatory mechanisms linking obesity and tendinopathy. J Orthop
  431 Translat. 2021 Dec 9;31:80–90.

 Table 1. Genetic loci associated with PMR at the genome-wide significance level.

rsID for lead variant	Variant position (Ch37/hg19)	Nearest gene	EA	NEA	EAF	Beta	SE	P value	OR	Previously known
rs11694915	2:102710068	IL1R1	А	Т	0.3865	-0.0978	0.0172	1.40E-08	0.91	No
rs748741	9:127089775	NEK6	A	G	0.6168	-0.0959	0.0172	2.31E-08	0.91	No
rs615540	11:64123838	CCDC88B	A	G	0.5489	0.1056	0.0169	3.70E-10	1.11	No
rs2760985	6:32566398	HLA-DRB1	A	G	0.2181	0.5307	0.0209	7.78E-142	1.70	Yes
rs7731626	5:55444683	ANKRD55	A	G	0.3123	-0.1618	0.0181	4.59E-19	0.85	Yes


EA, effect allele; EAF, effect allele frequency; NEA, non-effect allele; SE, standard error.

Figure 1. Results of genome-wide association study in PMR and summary of 5 identified genomic risk loci.



SNPs, single nucleotide polymorphisms.

Figure 2. Associations between genetically proxied modifiable factors and the risk of PMR in Mendelian randomization analysis.



Legend: FDR, false discovery rate correction for eight risk factors. Bars show 95% confidence interval. OR, odds ratio, estimate per standard deviation increase in all risk factors, except for coffee consumption (per 50% change in intake) and physical activity (being active verses inactive).







Figure 3. Associations between genetically predicted levels of inflammatory markers and the risk of PMR in Mendelian randomization analysis.

A. volcano plot of MR associations between 65 inflammatory markers and PMR. B. forest plot of 12 associations with P value < 0.05. Estimates were scaled to one standard deviation increase in genetically predicted markers.







value

-Log10 P